Butyricimonas virosa: the first clinical case of bacteraemia

Toprak, N. Ulger; Bozan, Turgut; Birkan, Yaşar; İşbir, Selim; Sõyletır, Gũner

doi:10.1016/j.nmni.2014.12.004

Cited by 28 publications

(30 citation statements)

References 6 publications

(4 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consistent with the report of Ulger Toprak et al. [1] , our isolate grew anaerobically on Brucella blood agar (Becton Dickinson, Franklin Lakes, NJ, USA), and on Gram stain appeared as a small Gram-negative rod. Our isolate was catalase positive and was resistant to kanamycin (1 mg), vancomycin (5 μg) and colistin sulfate (10 μg).…”

supporting

confidence: 91%

“…We read with interest the recent report by Ulger Toprak et al. [1] reporting the first case of Butyricimonas virosa bacteraemia published earlier this year. Here we describe the case of a 72-year-old man with colon cancer who presented with septic shock after aortic aneurysm surgery, with Butyricimonas virosa recovered from blood cultures.…”

mentioning

confidence: 92%

“…This phenotypic features were suggestive of a Prevotella spp. However, 16S rRNA sequencing demonstrated a 99% nucleotide identity with B. virosa [1] .…”

mentioning

confidence: 97%

See 2 more Smart Citations

Butyricimonas virosa bacteraemia identified by MALDI-TOF

Mehta

Estrada

Basallo

et al. 2015

New Microbes and New Infections

View full text Add to dashboard Cite

supporting

confidence: 91%

mentioning

confidence: 92%

See 1 more Smart Citation

Butyricimonas virosa bacteraemia identified by MALDI-TOF

Mehta

Estrada

Basallo

et al. 2015

New Microbes and New Infections

View full text Add to dashboard Cite

“…Ethanol-induced liver injury increased the relative abundance of Butyricimonas spp., which positively correlated with the levels of liver injury parameters such as AST and ALT (36). The species B. virosa has been reported to be associated with bacteremia (37)(38)(39). We also found that Oscillibacter spp.…”

Section: Discussionsupporting

confidence: 57%

Bifidobacterium longum R0175 Protects Rats against d -Galactosamine-Induced Acute Liver Failure

Wang

Ren

et al. 2020

mSphere

View full text Add to dashboard Cite

Acute liver failure is a severe liver disorder that poses considerable global challenges. Previous studies on Bifidobacterium longum R0175 have mainly focused on its psychotropic functions. The current research focused on the protective efficacy of B. longum R0175 against acute liver failure caused by d-galactosamine (d-GalN) in rats and further tested the hypothesis that B. longum R0175 exerted liver-protective effects by affecting the intestinal microbiota and fecal metabolites and by inhibiting inflammation. We found that oral gavage of B. longum R0175 markedly reduced the severity of liver injury in d-GalN-treated rats, as evidenced by decreased serum levels of aspartate aminotransferase (AST) and total bile acids (TBAs) (P < 0.05). Moreover, the plasma concentrations of proinflammatory cytokines (interleukin 1β [IL-1β] and tumor necrosis factor-α [TNF-α]) and chemokines (granulocyte-macrophage colony-stimulating factor [GM-CSF], macrophage chemoattractant protein 1 [MCP-1], chemokine [C-X-C motif] ligand 1 [CXCL1], chemokine [C-C motif] ligand 5 [CCL5], and macrophage inflammatory protein-1α [MIP-1α]) were also markedly reduced (P < 0.05). Pretreatment with B. longum R0175 partially reversed the gut microbiota dysbiosis in rats with liver injury by increasing the relative abundances of potentially beneficial bacteria, such as Alloprevotella spp., and decreasing the relative abundances of potentially harmful bacteria, such as Acetatifactor muris, Butyricimonas spp., and Oscillibacter spp. Furthermore, B. longum R0175 administration partially improved the metabolic function of the intestinal microbes, as indicated by the decreased level of lithocholic acid found in the feces. IMPORTANCE Our research investigated the protective and preventive roles of B. longum R0175 in a rat model of acute liver failure. The results illustrated that this probiotic strain exhibited protective effects in rats with acute liver failure. Thus, B. longum R0175 showed clinical application prospects that required further exploration.

show abstract

“…The family Porphyromonadaceae contains 11 genera: Porphyromonas (type genus) , Barnesiella, Butyricimonas, Dysgonomonas, Macellibacteroides, Odoribacter, Paludibacter, Parabacteroides, Petrimonas, Proteiniphilum and Tannerella [12] . Butyricimonas virosa bacteraemia has been described in patients with colon cancer [13] , [14] and in patients with posttraumatic chronic bone and joint infection [14] .…”

Section: Introductionmentioning

confidence: 99%

Butyricimonas phoceensis sp. nov., a new anaerobic species isolated from the human gut microbiota of a French morbidly obese patient

Togo

Diop

Dubourg

et al. 2016

New Microbes and New Infections

View full text Add to dashboard Cite

Butyricimonas phoceensis strain AT9 (= CSUR 2478 = DSM 100838) was isolated from a stool sample from a morbidly obese French patient living in Marseille using the culturomics approach. The genome of this Gram-negative-staining, anaerobic and non–spore forming rod bacillus is 4 736 949 bp long and contains 3947 protein-coding genes. Genomic analysis identified 173 genes as ORFans (4.5%) and 1650 orthologous proteins (42%) not shared with the closest phylogenetic species, Butyricimonas virosa. Its major fatty acid was the branched acid iso-C15:0 (62.3%).

show abstract

Butyricimonas virosa: the first clinical case of bacteraemia

Cited by 28 publications

References 6 publications

Butyricimonas virosa bacteraemia identified by MALDI-TOF

Butyricimonas virosa bacteraemia identified by MALDI-TOF

Bifidobacterium longum R0175 Protects Rats against d -Galactosamine-Induced Acute Liver Failure

Butyricimonas phoceensis sp. nov., a new anaerobic species isolated from the human gut microbiota of a French morbidly obese patient

Contact Info

Product

Resources

About